5-氯-3-羟基异噻唑 | 25629-58-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 5-氯-3-羟基异噻唑
• 英文名称: 5-chloroisothiazol-3(2H)-one
• 英文别名: 5-Chloroisothiazol-3-ol；5-chloro-1,2-thiazol-3-one
• CAS: 25629-58-7
• 化学式: C₃H₂ClNOS
• 分子量: 135.574
• InChiKey: XFIPRDRBFGJGIZ-UHFFFAOYSA-N

物化性质

• 熔点：
  96-97 °C(Solv: water (7732-18-5))
• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下

反应信息

• 作为反应物：
  描述：

  5-氯-3-羟基异噻唑 以81%的产率得到
  参考文献：
  名称：

  MATSUMOTO, KUNIOMI;MUNEHKATA, MIKIO;ISII, TADAO;VATANABEH, TEHTSURO

  摘要：

  DOI：
• 作为产物：
  描述：

  3-[(3-氨基-3-氧代丙基)二硫代]丙酰胺 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 以8.5%的产率得到5-氯-3-羟基异噻唑
  参考文献：
  名称：

  2-（4-取代的苯基）-3（2H）-异噻唑酮的合成和抗菌活性。

  摘要：

  合成了几种新的已知的2-（4-取代的苯基）-3（2H）-异噻唑酮衍生物，其在C-5位置处有或没有氯取代基，并评估了它们对所选革兰氏阴性和革兰氏阳性细菌的体外抗菌活性用琼脂稀释法。大多数化合物对被测微生物表现出中等至高活性，与参比药物相比，某些化合物具有可比或更高的活性。与以前的研究结果相反，与没有C-5取代的类似物相比，某些5-氯衍生物对某些被测微生物表现出较低或相当的活性。一般来说，

  DOI：

  10.1016/j.ejmech.2004.04.004

文献信息

• NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120157459A1

  公开（公告）日：2012-06-21

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一个以新型化合物作为活性成分的GPR40激活剂，该化合物具有GPR40激动剂作用，该化合物的盐，该盐或化合物的溶剂合物，或者类似物，尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A是一个芳基团，可选择性被L取代或是一个杂环团，可选择性被L取代；环B是一个苯环、一个吡啶环或一个嘧啶环；X是O，S，—NR7—；R1至R7是特定基团），该化合物的盐，或该盐或化合物的溶剂合物。
• [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017212425A1

  公开（公告）日：2017-12-14

  The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及替代哌啶衍生物。具体而言，该发明涉及符合以下式III的化合物：其中A、B、X、Y、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、z2、z4、z5和z6如本文所定义，并其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病及相关朊蛋白病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
• 2-(3-oxoalk(en)yl)-3-isothiazolones and derivatives as antimicrobial
  申请人：Rohm and Haas Company

  公开号：US05288693A1

  公开（公告）日：1994-02-22

  Antimicrobial compounds of the formula ##STR1## wherein R is hydrogen, halogen or (C.sub.1 -C.sub.4)alkyl group; R.sub.1 is hydrogen or halogen; alternatively, R and R1 may be taken together with the carbons to which they are attached to form a 5- to 7-membered carbocyclic ring, said ring optionally being aromatic; R.sub.2 is hydrogen or (C.sub.1 -C.sub.3)alkyl group; and R3 is hydrogen, substituted or unsubstituted (C.sub.1 -C.sub.18)alkyl, substituted or unsubstituted (C.sub.2 -C.sub.18)alkenyl, substituted or unsubstituted (C.sub.2 -C.sub.18)alkynyl, substituted or unsubstituted (C.sub.4 -C.sub.8)cycloalkyl or cycloalkenyl, substituted or unsubstituted (C.sub.6 -C.sub.10)aryl or arylalkyl group are disclosed.

  化学式为##STR1##的抗微生物化合物，其中R为氢、卤素或(C.sub.1 -C.sub.4)烷基基团；R.sub.1为氢或卤素；或者，R和R1可以与它们附着的碳一起形成一个5至7成员的碳环，该环可以选择性地是芳香的；R.sub.2为氢或(C.sub.1 -C.sub.3)烷基基团；R3为氢、取代或未取代的(C.sub.1 -C.sub.18)烷基、取代或未取代的(C.sub.2 -C.sub.18)烯基、取代或未取代的(C.sub.2 -C.sub.18)炔基、取代或未取代的(C.sub.4 -C.sub.8)环烷基或环烯基、取代或未取代的(C.sub.6 -C.sub.10)芳基或芳基烷基基团。
• [EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR X FARNÉSOÏDE ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2017049173A1

  公开（公告）日：2017-03-23

  Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

  本文描述了一些具有法尼索X受体激动剂作用的化合物，制备这些化合物的方法，包含这些化合物的药物组合物和药物，以及使用这些化合物治疗与法尼索X受体活性相关的疾病、疾病或疾病的方法。
• CYCLIC AMIDE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20130203739A1

  公开（公告）日：2013-08-08

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR 7 —; J 1 is —CR 11a R 11b — or —NR 11c —; J 2 is —CR 12a R 12b — or —NR 12c —; and R 1 to R 12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物，尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂，解决问题的方法是使用Formula (1)的化合物：(其中n为0至2；p为0至4；h为0至3；j为0至3；k为0至2；环B为芳香族或杂环芳基；X为O、S或-NR7-；J1为-CR11aR11b-或-NR11c-；J2为-CR12aR12b-或-NR12c-；R1到R12为特定基团)，该化合物的盐，或盐或化合物的溶剂合物。